Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma - Wikidata - awgldk - TriplyDB

Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma

Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma

http://www.wikidata.org/entity/Q59218456

about

Trial Watch: Proteasomal inhibitors for anticancer therapy Blocking autophagy prevents bortezomib-induced NF-κB activation by reducing I-κBα degradation in lymphoma cells The expression of FAS-associated factor 1 and heat shock protein 70 in ovarian cancer.Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era Proteasome inhibitors in the treatment of multiple myeloma Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.Nuclear translocation of B-cell-specific transcription factor, BACH2, modulates ROS mediated cytotoxic responses in mantle cell lymphoma.NF-kappaB and cancer: how intimate is this relationship Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma.Redox-regulated pathway of tyrosine phosphorylation underlies NF-κB induction by an atypical pathway independent of the 26S proteasome.Proteotoxic crisis, the ubiquitin-proteasome system, and cancer therapy.The expression of the endoplasmic reticulum stress sensor BiP/GRP78 predicts response to chemotherapy and determines the efficacy of proteasome inhibitors in diffuse large b-cell lymphoma Anti-β₂-microglobulin monoclonal antibodies overcome bortezomib resistance in multiple myeloma by inhibiting autophagy.Sensitizing human multiple myeloma cells to the proteasome inhibitor bortezomib by novel curcumin analogs.Microscale functional cytomics for studying hematologic cancers Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma via manipulation of tissue transglutaminase activities Bortezomib-resistant nuclear factor κB expression in stem-like cells in mantle cell lymphoma.Verapamil synergistically enhances cytotoxicity of bortezomib in mantle cell lymphoma via induction of reactive oxygen species production.Bortezomib for the treatment of non-Hodgkin's lymphoma Signalling pathway activation by photodynamic therapy: NF-κB at the crossroad between oncology and immunology.(Immuno)proteasomes as therapeutic target in acute leukemia.Perturbation of proteasome function by bortezomib leading to ER stress-induced apoptotic cell death in cholangiocarcinoma.

P2860

Q28082910-C901619B-2F0C-43EE-B0B3-61A47B584AE8 Q28481321-06F55B38-FF95-46FF-9471-C46DC8554395 Q34011778-0664124D-7E25-4BF9-B540-9740C5214B49 Q34542087-41A33548-4BC6-4648-8E8F-963BCE093575 Q34568868-001456FE-4464-45FC-B897-5A19397317A3 Q34611676-4CD18BD9-B24A-4EBA-AD45-CA8EF24BC042 Q34788381-B3C1375F-4C4C-41CB-8456-91392AD05E5F Q34924231-26BCA335-5E4D-4616-B889-1087213B5FF7 Q35143597-DCB2FDF2-F1D0-4778-BC35-7F00F326647B Q35146262-C94BCA1E-8842-49B7-862D-C18115FDDFC8 Q35255425-F597CD50-4380-4B55-B0B4-B54C5BEEC251 Q35408665-1D109A93-987C-46ED-8106-7C2A7CD81140 Q35475256-47C4836E-0D6A-4459-9A82-96814CB53B1A Q35832168-8E41286C-6A33-4F29-B415-10B7F35EF895 Q35840019-D71F4A81-DE82-484E-A2F4-83C5CE8AABDE Q35849287-F9C84C52-9453-461B-93DC-EC233A3CD2C3 Q35849327-A620006E-D9FF-4EC8-885D-5AB8C6A0DBF3 Q36099655-F5E7F735-D912-4B67-B99B-FD97F5B9871A Q36285148-40B0EADA-7AB1-4EAC-A207-61342CA2EE26 Q36868056-BDF10200-943A-4BB3-9068-CF10541C6309 Q38345816-8DEFE0A4-776A-45DF-A788-10704C4E53E4 Q47131929-C9C5BBD8-2E71-46CC-AF32-D25766E097EB Q47955863-7E96AAD0-82E3-405F-9876-02E3F0664272

P2860

Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma

http://www.wikidata.org/entity/Q59218456

description

article

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в травні 2008

@uk

name

Prevalence of bortezomib-resis ...... tivity in mantle cell lymphoma

@en

Prevalence of bortezomib-resis ...... tivity in mantle cell lymphoma

@nl

type

label

Prevalence of bortezomib-resis ...... tivity in mantle cell lymphoma

@en

Prevalence of bortezomib-resis ...... tivity in mantle cell lymphoma

@nl

prefLabel

Prevalence of bortezomib-resis ...... tivity in mantle cell lymphoma

@en

Prevalence of bortezomib-resis ...... tivity in mantle cell lymphoma

@nl

P1433

Q59218456-B92143A9-5D88-4250-98A7-80E26D381817

P1476

Q59218456-62C505D8-846E-40FE-B57B-42C3A7666913

P2093

Q59218456-378B5759-BEE2-4277-8A2C-EB42CCE94ABF

Q59218456-55ECB9F8-0BAD-4026-A9E5-6E4E5D0375DA

Q59218456-64D82B37-70CA-46E2-B3FF-5AA46D9DE998

Q59218456-A6791605-7887-4EEB-A069-441D9F5B9111

Q59218456-D081309C-A8A6-46D5-8815-FFE31263BAD0

P2888

Q59218456-546ADE36-DA44-4843-ADA7-8002C9D6F83E

P304

Q59218456-C9DA4EC4-E1CF-4157-8B33-36A89E653FE9

P31

Q59218456-71F07455-EF79-43B0-B87A-9611E9FC2C90

P356

Q59218456-9B51DDA7-8929-472E-9237-C15E28B639FC

P407

Q59218456-0588F612-AD4C-4D98-939F-4C5FCFD4965C

P433

Q59218456-8A9921C7-2F6B-4ECF-AFFC-4B7563AAB60A

P478

Q59218456-E8415E2F-ACE2-4CEC-B635-AB94C81C0EE7

P577

Q59218456-0C5EEE8B-B647-4115-94C6-5741F425BFB5

P6179

Q59218456-54374E70-F8D2-42C7-9B36-9A81A0687EC8

P698

Q59218456-A517BA2B-A414-46F9-B4D0-46FEEB016FE7

P932

Q59218456-0F34A12C-1279-4BC0-B41F-6DD2CC4C13C9

P356

P1433

Molecular Cancer

P1476

Prevalence of bortezomib-resis ...... tivity in mantle cell lymphoma

@en

P2093

Brad S Kahl

http://www.w3.org/2001/XMLSchema#string

David T Yang

http://www.w3.org/2001/XMLSchema#string

Ken H Young

http://www.w3.org/2001/XMLSchema#string

Shigeki Miyamoto

http://www.w3.org/2001/XMLSchema#string

Stephanie Markovina

http://www.w3.org/2001/XMLSchema#string

P2888

P304

40

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1476-4598-7-40

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2008-05-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1009740223

http://www.w3.org/2001/XMLSchema#string

P698

18489772

http://www.w3.org/2001/XMLSchema#string

P932

2408930

http://www.w3.org/2001/XMLSchema#string